ArticleESMO gastrointestinal oncology2026
Immune checkpoint inhibitor-induced myocarditis with atrioventricular conduction abnormalities: a case report.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of several cancer types, but can cause immune-related adverse events (irAEs) such as myocarditis. ICI-induced myocarditis is rare but potentially life threatening and may present with subtle or atypical symptoms, including conduction abnormalities. We describe a case of nivolumab-induced myocarditis in a patient receiving adjuvant therapy for esophageal cancer, presenting with high-grade atrioventricular block and neuromuscular symptoms, highlighting the diagnostic and therapeutic challenges of ICI-induced myocarditis. The case underscores the importance of early recognition, comprehensive diagnostic evaluation, prompt initiation of immunosuppressive therapy, and individualized management of conduction disturbances. Early detection and intervention are key to mitigating risks and improving outcomes in this rare but serious irAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.